Patents by Inventor Jay Theroff

Jay Theroff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLS1 inhibitors for treating disease
    Patent number: 11958849
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: April 16, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20230124815
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: April 25, 2022
    Publication date: April 20, 2023
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • GLS1 inhibitors for treating disease
    Patent number: 11370786
    Abstract: Disclosed herein are compounds of structural Formula VIIa or VIIb: or a pharmaceutically acceptable salt thereof, and compositions thereof useful in the treatment of GLS1 mediated diseases, such as cancer. Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: June 28, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • HETEROCYCLIC INHIBITORS OF TYROSINE KINASE
    Publication number: 20220194940
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.
    Type: Application
    Filed: April 24, 2020
    Publication date: June 23, 2022
    Inventors: John HEYMACH, Jacqulyne ROBICHAUX, Monique NILSSON, Philip JONES, Jason CROSS, Jay THEROFF
  • Heterocyclic inhibitors of tyrosine kinase
    Patent number: 11365189
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: June 21, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: John Heymach, Jacqulyne Robichaux, Monique Nilsson, Philip Jones, Jason Cross, Jay Theroff
  • Heterocyclic modulators of HIF activity for treatment of disease
    Patent number: 11001594
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: May 11, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip Jones, Maria Emilia Di Francesco, Alessia Petrocchi, Christopher L. Carroll, Joe Marszalek, Barbara Czako, Ryan Johnson, Jay Theroff
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20200407353
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: July 10, 2020
    Publication date: December 31, 2020
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • HETEROCYCLIC INHIBITORS OF TYROSINE KINASE
    Publication number: 20200354343
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.
    Type: Application
    Filed: April 24, 2020
    Publication date: November 12, 2020
    Inventors: John HEYMACH, Jacqulyne ROBICHAUX, Monique NILSSON, Philip JONES, Jason CROSS, Jay THEROFF
  • GLS1 inhibitors for treating disease
    Patent number: 10766892
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: September 8, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20190270736
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: May 14, 2019
    Publication date: September 5, 2019
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
    Publication number: 20190270753
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
    Type: Application
    Filed: December 21, 2018
    Publication date: September 5, 2019
    Inventors: Philip JONES, Maria Emilia DI FRANCESCO, Alessia PETROCCHI, Christopher L. CARROLL, Joe MARSZALEK, Barbara CZAKO, Ryan JOHNSON, Jay THEROFF
  • GLS1 inhibitors for treating disease
    Patent number: 10344025
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: July 9, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • Heterocyclic modulators of HIF activity for treatment of disease
    Patent number: 10208059
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: February 19, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip Jones, Maria Emilia Di Francesco, Alessia Petrocchi, Christopher L. Carroll, Joe Marszalek, Barbara Czako, Ryan Johnson, Jay Theroff
  • GLS1 inhibitors for treating disease
    Patent number: 9809588
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: November 7, 2017
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20170291895
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: June 15, 2017
    Publication date: October 12, 2017
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
    Publication number: 20170121342
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
    Type: Application
    Filed: October 4, 2016
    Publication date: May 4, 2017
    Inventors: Philip Jones, Maria Emilia Di Francesco, Alessia Petrocchi, Christopher L. Carroll, Joe Marszalek, Barbara Czako, Ryan Johnson, Jay Theroff
  • Heterocyclic modulators of HIF activity for treatment of disease
    Patent number: 9481692
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: November 1, 2016
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip Jones, Maria Emilia DiFrancesco, Alessia Petrocchi, Christopher L. Carroll, Joe Marszalek, Barbara Czako, Ryan Johnson, Jay Theroff
  • BROMODOMAIN INHIBITORS FOR TREATING DISEASE
    Publication number: 20160060260
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of bromodomain-containing protein-mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibiting activity of a bromodomain-containing protein in a human or animal subject are also provided.
    Type: Application
    Filed: August 28, 2015
    Publication date: March 3, 2016
    Applicant: Board of Regents, The University of Texas System
    Inventors: Wylie Palmer, Philip Jones, Gang Liu, Alessia Petrocchi, Naphtali Reyna, Govindan Subrumanian, Jay Theroff, Anne Yau
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20160009704
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: July 2, 2015
    Publication date: January 14, 2016
    Applicant: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20160002248
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: July 2, 2015
    Publication date: January 7, 2016
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Maria Emilia Di Francesco, Timothy Heffernan, Michael J. Soth, Kang Le, Christopher Lawrence Carroll, Timothy McAfoos, Jason P. Burke, Jay Theroff, Zhijun Kang, Philip Jones